BPTH.US Bio Path Holdings Inc

Healthcare Biotechnology USA Stocks
0.0003 USD
Close of Nov 14, 2026
0.0001 0.1000
Market cap
USD 15.1K
P/E
-
P/B
1.90x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Mar 2026.

Is BPTH.US undervalued?

Graham number

The Graham number of Bio Path Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bio Path Holdings Inc fundamental analysis

No fundamental analysis for Bio Path Holdings Inc yet.

Bio Path Holdings Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bio Path Holdings Inc

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company'…

Full company profile